CUE beat EPS expectations by 30.26%
Aug 21, 2024, 9:36 AM
0.00%
What does CUE do
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company based in Boston, focuses on developing injectable biologics that modulate tumor-specific T cells for treating cancers and autoimmune diseases. Their lead products, including CUE-101 for HPV-driven cancers and CUE-102 targeting WT-1 protein, leverage their proprietary Immuno-STAT platform.
Cue Biopharma (CUE) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cue Biopharma's actual EPS was -$0.20, beating the estimate of -$0.29 per share, resulting in a 30.26% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.